Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.
Class II · Ongoing
Presence of particulate matter: a white thread-like structure in the cartridge
Advertisement
Advertisement
Affected lots / codes — check yours against thisLots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.
- Recalling firm
- Lupin Pharmaceuticals Inc., Naples, FL
- Classification
- Class II (temporary or reversible harm possible)
- Status
- Ongoing
- Quantity
- 217,621 pen injectors
- Distribution
- Nationwide within U.S
- Recall initiated
- April 24, 2026
- Classified
- May 19, 2026
- Initiation
- Voluntary: Firm initiated
Advertisement
Official source. This record is published by the U.S. FDA through the openFDA
enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0541-2026%22
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0541-2026%22
Advertisement
Important. Recalls target specific lots and codes — compare the affected lots
above against your own product. This page reproduces public FDA data for readability;
EveryRecall is independent and not affiliated with the FDA.
Check this brand across all 8 databases →